Currently, SoftVue is available at the Karmanos Cancer Institute and Karmanos patients may sign up to be part of the ongoing clinical studies. Once the first FDA clearance is secured, additional SoftVue systems will be produced and placed in other medical centers interested in this technology.
For more information on SoftVue technology contact Delphinus Medical Technologies at 734-233-3088. For patients interested in participating in SoftVue's clinical studies for breast cancer screening, call the Karmanos Cancer Institute at 1-800-KARMANOS (1-800-527-6266.)
About the Barbara Ann Karmanos Cancer Institute
Located in mid-town Detroit, Michigan, the Barbara Ann Karmanos Cancer Institute is one of 41 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for nearly 6,000 new patients annually on a budget of $265 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, Karmanos is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 physicians and researchers on faculty at the Wayne State University School of Medicine, and supported by thousands of volunteer and financial donors, Karmanos strives to prevent, detect and eradicate all forms of cancer. Its long-term partnership with the WSU School of Medicine enhances the collaboration of critical research and academics related to cancer care. Gerold Bepler, M.D., Ph.D., is the Institute's president and chief executive officer. For more information call 1-800-KARMANOS or go to
About Delphinus Medical Technologies
Delphinus Medical Technologies, Inc, is a Michigan-based company and a spin-off of the Barbara Ann Karmanos Cancer Institute (KCI). Delphinus has succeeded in building a three-dimensional, whole-breast ultrasound imaging device using a safe (non-ionizing), comfortable (non-compressing), and reliable (operator independent) patented technology.
The system is not dependent on the skills of the operator and it is fast, with exam times of approximately one minute. Furthermore, SoftVue does not require expensive room preparations making it easy to install in any clinical setting. KCI has transferred all the UST intellectual property to Delphinus Medical Technologies through a worldwide license to commercialize the SoftVue technology.
Delphinus is located in the Michigan LifeScience and Innovation Center at 46701 Commerce Center Drive, in Plymouth, MI. Delphinus has subcontracted with partners to produce its commercial system.
Delphinus's business model is based on the sales and service of the SoftVue system to hospitals and imaging clinics throughout the United States and the rest of the world. The company plans to use dealer sales organizations in the U.S. for the distribution of the product. In the rest of the world the company will partner with large distributors, or imaging Original Equipment Manufacturers (OEM) looking for an entry into the breast cancer screening market. Delphinus plans to do final assembly and testing of SoftVue through subcontracted manufacturing.
SoftVue has not received market clearance from the FDA at this time.
SOURCE Karmanos Cancer Institute